SEC Tracker
Get the app

Editas Medicine EDIT

Gilmore Neil O'Neill (CEO) received 43,567 EDIT

Form
4
Filed
Importance
Routine
  1. CEO Neil O'Neill acquired 43,567 common shares on Nov 5, 2026
  2. Shares acquired via vesting of restricted stock units (shares paid out over time)
  3. Post-transaction, 286,756 shares owned

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Editas Medicine files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Merus MRUS
  2. Palvella Therapeutics PVLA public float $197M, Jun 30, 2025
  3. Esperion Therapeutics ESPR public float $198M, Jun 30, 2025
  4. Rezolute RZLT public float $204M, Dec 31, 2025
  5. Cardiff Oncology CRDF public float $205M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.